USPTO Examiner MCGARRY SEAN - Art Unit 1635

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18819435MODELS OF TAUOPATHYAugust 2024April 2025Allow810NoNo
18765750SAMPLE SPLITTING FOR MULTIPLEXED DETECTION OF NUCLEIC ACIDS WITHOUT AMPLIFICATIONJuly 2024February 2025Allow710NoNo
18673713TRANS-SPLICING MOLECULESMay 2024June 2025Allow1300NoNo
18441280COMPOSITIONS AND THERAPEUTIC METHODS OF MICRORNA GENE DELIVERYFebruary 2024April 2025Allow1410NoNo
18407780Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target CellJanuary 2024September 2024Allow810NoNo
18407815Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target CellJanuary 2024March 2024Allow200NoNo
18406159SAMPLE SPLITTING FOR MULTIPLEXED DETECTION OF NUCLEIC ACIDS WITHOUT AMPLIFICATIONJanuary 2024June 2024Allow600NoNo
18392181Methods Of Treating Decreased Bone Mineral Density With Cluster Of Differentiation 109 (CD109) InhibitorsDecember 2023October 2024Allow1010NoNo
18512207Aptamers For Personal Health Care ApplicationsNovember 2023March 2025Allow1620NoNo
18511108DNA Monoclonal Antibodies Targeting Influenza VirusNovember 2023May 2025Allow1820NoNo
18502516MODELS OF TAUOPATHYNovember 2023June 2024Allow700NoNo
18503125SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCERNovember 2023March 2025Allow1620NoNo
18381238DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULESOctober 2023December 2024Abandon1401NoNo
18487429SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCEROctober 2023November 2024Allow1320NoNo
18368248APPARATUS, METHOD, AND USE FOR ULTRASOUND MEDIATED MICROBUBBLE DELIVERY OF PHARMACEUTICAL COMPOSITIONSSeptember 2023October 2024Abandon1301NoNo
18450033VIRAL VECTOR PRODUCTIONAugust 2023February 2025Allow1810NoNo
18448254METHODS FOR PRODUCTION OF MSC-DERIVED EXOSOMESAugust 2023June 2025Allow2211NoNo
18356404Methods for Treatment of Alport SyndromeJuly 2023October 2024Abandon1510NoNo
18345452ANGELMAN SYNDROME ANTISENSE TREATMENTJune 2023September 2024Allow1420NoNo
18342409CONJUGATED ANTISENSE COMPOUNDS AND THEIR USEJune 2023December 2024Allow1810NoNo
18205390NUCLEOLIN-TARGETING APTAMERS AND METHODS OF USING THE SAMEJune 2023January 2025Allow2011NoNo
18316556Albumin Production and Cell ProliferationMay 2023September 2024Abandon1610NoNo
18315890MODULATING APOLIPOPROTEIN (A) EXPRESSIONMay 2023April 2025Allow2420NoNo
18296912SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDESApril 2023November 2023Allow710NoNo
18128949ANTIDOTE-MEDIATED REVERSAL OF EXTRACELLULAR APTAMER STAININGMarch 2023May 2025Allow2510NoNo
18168066Screening artificial nucleic acids by particle displayFebruary 2023February 2025Allow2412NoNo
18165113SELECTIVE INHIBITION OF T FOLLICULAR HELPER CELLS FOR TREATMENT OF AUTOIMMUNE DISORDERSFebruary 2023August 2024Allow1810NoNo
18155945COMPOSITIONS FOR MODULATING TAU EXPRESSIONJanuary 2023March 2024Allow1410NoNo
18080049METHOD FOR TREATING CARDIOVASCULAR DISEASEDecember 2022November 2024Abandon2320NoNo
18055525METHODS AND COMPOSITIONS FOR THE ACTIVATION OF GAMMA-DELTA T-CELLSNovember 2022April 2025Allow2911NoNo
18055212ANGLEMAN SYNDROME ANTISENSE TREATMENTNovember 2022June 2023Allow720NoNo
18053679ANTISENSE NUCLEIC ACIDSNovember 2022October 2024Abandon2310NoNo
17982469C5a Binding Nucleic AcidsNovember 2022August 2024Allow2200NoNo
18051821METHODS AND COMPOSITIONS FOR THE ACTIVATION OF GAMMA-DELTA T-CELLSNovember 2022May 2025Allow3011NoNo
18051487AMPHIPHILIC POLYNUCLEOTIDESOctober 2022December 2023Allow1301NoNo
18045357TREATING METASTATIC CANCER AND MODEL SYSTEMS FOR METASTATIC DISEASEOctober 2022March 2024Allow1710NoNo
17930364MODULATORS AND MODULATION OF THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS RNASeptember 2022January 2023Allow510NoNo
17895007ANTICANCER COMPOSITIONS AND METHODS FOR MAKING AND USING THEMAugust 2022February 2024Allow1810NoNo
17892686COMPOSITIONS AND METHODS FOR IDENTIFYING POLYNUCLEOTIDES OF INTERESTAugust 2022May 2024Allow2001NoNo
17816059MTOR-INHIBITOR-CONTAINING MEDICINE FOR TREATING OR PREVENTING OPHTHALMIC SYMPTOMS, DISORDERS, OR DISEASES, AND APPLICATION THEREOFJuly 2022March 2025Allow3121NoNo
17816084Methods Of Treating Decreased Bone Mineral Density With Cluster Of Differentiation 109 (CD109) InhibitorsJuly 2022September 2023Allow1410NoNo
17812576TRANSLATABLE MOLECULES AND SYNTHESIS THEREOFJuly 2022November 2023Allow1610NoNo
17861676METHOD FOR REDUCING THE EXPRESSION OF NKCC1 IN A SUBJECTJuly 2022July 2024Abandon2510NoNo
17860141STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOFJuly 2022June 2024Abandon2401NoNo
17852939Compounds and Methods for Reducing ATXN3 ExpressionJune 2022July 2023Allow1200NoNo
17849294TWIST SIGNALING INHIBITOR COMPOSITIONS AND METHODS OF USING THE SAMEJune 2022October 2023Allow1610NoNo
17844877Heterologous UTR Sequences for Enhanced mRNA ExpressionJune 2022January 2024Allow1801NoNo
17746387METHODS OF INDUCING INSULIN PRODUCTIONMay 2022April 2024Abandon2301NoNo
17724176COMPOSITIONS AND METHODS FOR INHIBITING NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 3 (NR1H3) EXPRESSIONApril 2022July 2022Allow300NoNo
17716497Pan-Genotypic Agents Against Influenza Virus and Methods of Using the SameApril 2022August 2024Abandon2801NoNo
17714196ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFApril 2022June 2022Allow200NoNo
17694482CD44 APTAMERMarch 2022July 2023Allow1601NoNo
17692048METHODS AND COMPOSITIONS TO DIRECT BREAKDOWN OF INSULIN MRNA IN BENIGN FASHIONMarch 2022May 2025Abandon3821NoNo
17668504INHIBITION OF KMT2D FOR THE TREATMENT OF CANCERFebruary 2022May 2023Allow1500NoNo
17570313COMBINATION VECTORS AND METHODS FOR TREATING CANCERJanuary 2022March 2025Allow3812NoNo
17569658THERAPEUTIC ALTERATION OF TRANSPLANTABLE TISSUES THROUGH IN SITU OR EX VIVO EXPOSURE TO RNA INTERFERENCE MOLECULESJanuary 2022May 2024Allow2820YesNo
17645895APPLICATION OF AGENT IN PREPARATION OF MEDICINE FOR TREATING/INHIBITING PSORIASISDecember 2021April 2025Abandon4021NoNo
17531913ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFNovember 2021July 2023Allow2010NoNo
17531921ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFNovember 2021July 2023Allow2010NoNo
17531885ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFNovember 2021March 2022Allow310NoNo
17531900ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFNovember 2021March 2022Allow310NoNo
17531919ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFNovember 2021July 2023Allow2010NoNo
17531888ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOFNovember 2021March 2022Allow310NoNo
17523456ANGELMAN SYNDROME ANTISENSE TREATMENTNovember 2021April 2023Allow1710NoNo
17610000DIMERIC CPG OLIGONUCLEOTIDES FOR USE IN MODULATING IMMUNE RESPONSESNovember 2021May 2025Abandon4201NoNo
175178912'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONSNovember 2021September 2024Abandon3510NoNo
17607616PD-L1 antisense oligonucleotides for use in tumor treatmentOctober 2021May 2025Abandon4311NoNo
17604707MOLECULAR MARKER DETECTION AND REGULATING METHODS IN DE-SERVITIZATION STATE OF CELLSOctober 2021April 2025Allow4211NoNo
17602740NUCLEIC ACID NANOSTRUCTURES CROSSLINKED WITH OLIGOLYSINEOctober 2021December 2024Allow3800NoNo
17493112METHODS AND COMPOSITIONS FOR INHIBITING PMP22 EXPRESSIONOctober 2021December 2023Allow2610NoNo
17490611ADENO-ASSOCIATED VIRAL VECTORS USEFUL IN TREATMENT OF SPINAL MUSCULAR ATROPYSeptember 2021October 2023Abandon2501NoNo
17486488HIGH-EFFICIENCY RECONSTITUTION OF RNA MOLECULESSeptember 2021June 2025Allow4511NoNo
17484386COMPOUNDS AND METHODS FOR MODULATING TMPRSS6 EXPRESSIONSeptember 2021July 2023Abandon2210NoNo
17442301COMPOSITIONS AND METHODS FOR THE TREATMENT OF KRAS ASSOCIATED DISEASES OR DISORDERSSeptember 2021January 2025Abandon4001NoNo
17475795OLIGONUCLEOTIDES TO TREAT EYE DISEASESeptember 2021November 2023Abandon2610NoNo
17473209ARC-BASED CAPSIDS AND USES THEREOFSeptember 2021July 2022Abandon1001NoNo
17469530AGENTS AND METHODS FOR TREATING PANCREATIC DUCTAL ADENOCARCINOMASSeptember 2021June 2024Allow3310NoNo
17436721microRNA Expression Promoting Agent and Food or Beverage for Promoting Expression of microRNASeptember 2021February 2025Allow4120NoNo
17461797IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USEAugust 2021May 2024Abandon3211NoNo
17434317INFLAMMASOME-TARGETED RNA INTERFERENCE APPROACH TO TREATING KIDNEY INJURY AND DISEASEAugust 2021January 2025Allow4111NoNo
17411932MODULATORS AND MODULATION OF THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS RNAAugust 2021July 2022Allow1111NoNo
17411313MODULATING THE CELLULAR STRESS RESPONSEAugust 2021July 2024Allow3521YesNo
17411265SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCERAugust 2021June 2023Allow2210NoNo
17408920Compositions and Methods for Modulating MECP2 ExpressionAugust 2021March 2025Allow4212NoNo
17432720ANTIBODIES AND ENONOMERSAugust 2021June 2025Allow4631NoNo
17402459DUAL TARGETING siRNA AGENTSAugust 2021September 2023Abandon2501NoNo
17310579METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF CYP27A1August 2021January 2025Abandon4101NoNo
17396760COMBINATION OF VACCINATION AND OX40 AGONISTSAugust 2021August 2024Allow3611NoNo
17375877ANTISENSE NUCLEIC ACIDSJuly 2021January 2022Abandon610YesNo
17369783MRNA THERAPY FOR POMPE DISEASEJuly 2021March 2023Allow2010NoNo
17367096MODULATION OF PREKALLIKREIN (PKK) EXPRESSIONJuly 2021July 2023Allow2401NoNo
17366796Methods for Treatment of Alport SyndromeJuly 2021October 2023Abandon2820NoNo
17366835LOCALIZED THERAPY OF LOWER AIRWAYS INFLAMMATORY DISORDERS WITH PROINFLAMMATORY CYTOKINE INHIBITORSJuly 2021March 2023Allow2010NoNo
17359905Compositions and Methods for Treating CancerJune 2021March 2025Allow4411NoNo
17356828Aptamers For Personal Health Care ApplicationsJune 2021November 2023Allow2811NoNo
17353559INSECT CONTROL STRATEGIES UTILITIZING PHEROMONES AND RNAIJune 2021August 2023Abandon2611NoNo
17312326NUCLEIC ACID BIOMARKERS FOR PLACENTAL DYSFUNCTIONJune 2021October 2024Abandon4101NoNo
17311970METHODS OF DETECTING, PREVENTING, REVERSING, AND TREATING NEUROLOGICAL DISEASESJune 2021July 2025Allow4912NoNo
17337762MODULATION OF LNC05 EXPRESSIONJune 2021May 2023Abandon2410NoNo
17298803SHORT DNA APTAMERS AND METHODS FOR PROMOTING REMYELINATIONJune 2021February 2024Allow3300NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MCGARRY, SEAN.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
3
Examiner Affirmed
2
(66.7%)
Examiner Reversed
1
(33.3%)
Reversal Percentile
48.3%
Lower than average

What This Means

With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
49
Allowed After Appeal Filing
14
(28.6%)
Not Allowed After Appeal Filing
35
(71.4%)
Filing Benefit Percentile
38.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 28.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MCGARRY, SEAN - Prosecution Strategy Guide

Executive Summary

Examiner MCGARRY, SEAN works in Art Unit 1635 and has examined 959 patent applications in our dataset. With an allowance rate of 61.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.

Allowance Patterns

Examiner MCGARRY, SEAN's allowance rate of 61.4% places them in the 15% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MCGARRY, SEAN receive 1.22 office actions before reaching final disposition. This places the examiner in the 21% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MCGARRY, SEAN is 30 months. This places the examiner in the 39% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +22.5% benefit to allowance rate for applications examined by MCGARRY, SEAN. This interview benefit is in the 71% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 30.9% of applications are subsequently allowed. This success rate is in the 54% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 60.3% of cases where such amendments are filed. This entry rate is in the 82% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 90.0% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 88.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 62.9% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 9.1% of allowed cases (in the 95% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.8% of allowed cases (in the 81% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.